Who is sponsoring NCT06230861?

NCT06230861 is sponsored by University of Central Lancashire.

What condition does NCT06230861 study?

NCT06230861 studies Cardiometabolic Syndrome.

What drugs are being tested in NCT06230861?

Interventions: Quercetin, Placebo.

What is the status of NCT06230861?

NCT06230861 is currently RECRUITING.

Last reviewed 2026-02-27 · How we verify

Effects of Quercetin on Cardiometabolic Outcomes

NCT06230861 NA RECRUITING

Cardiovascular disease, type 2 diabetes mellitus and associated diseases combined are the leading health burden and cause of mortality worldwide; therefore, the necessity for an intervention is paramount. Dietary interventions to improve cardiometabolic health are highly sought after as they possess less risk than pharmacological drugs. It has been postulated that Quercetin may be beneficial in improving cardiometabolic outcomes. However, to date, no research has explored this using a placebo randomized intervention.

Details

Lead sponsor	University of Central Lancashire
Phase	NA
Status	RECRUITING
Enrolment	40
Start date	Fri Mar 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Cardiometabolic Syndrome

Interventions

Quercetin
Placebo

Countries

United Kingdom